Rho family proteins are key components in cellular processes that control the organization of the actin cytoskeleton, activate kinase cascades, regulate gene expression, regulate membrane ...

The OCU400 Phase 3 clinical trial will enroll 150 participants - one group composed of 75 participants with the RHO gene mutation and the other with 75 participants that are gene agnostic.

The study includes 150 subjects divided into two arms, with one focusing on patients with RHO gene mutations and the other being gene-agnostic. According to InvestingPro data, while Ocugen ...